Slingshot members are tracking this event:

Phase 3 Study of BLINCYTO (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia; Study Stopped Early for Efficacy

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AMGN Community voting in process

Additional Information

Additional Relevant Details  The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO (blinatumomab) versus standard of care (SOC) in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The independent data monitoring committee recommended, and Amgenhas accepted, that the study end early for efficacy.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 04, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Blincyto, Blinatumomab, Primary Endpoint, B-cell Lymphoblastic Leukeia